Application of QDSA Platform in Cerebrovascular Diseases
ConditionCerebrovascular Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age1-80
SponsorBeijing Tiantan Hospital
About this trial
Cerebrovascular diseases pose a major global public health challenge, characterized by exceptionally high mortality and disability rates, with their pathogenesis closely linked to hemodynamic abnormalities. The quantitative digital subtraction angiography (QDSA) analysis platform, leveraging its advantages of vessel modeling-free operation, high computational efficiency, and DSA-equivalent sensitivity, has emerged as a novel hemodynamic assessment method with significant clinical potential. This study aims to establish a cerebrovascular disease cohort incorporating QDSA parameters to systematically validate the clinical value of this technology in preoperative evaluation and surgical planning, thereby providing evidence-based insights for optimizing diagnostic and therapeutic strategies.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Cerebrovascular diseases diagnosed and assessed by DSA for related risks and treatment options.
The DSA acquisition protocol complies with the standard procedure.
DSA images must include complete anteroposterior and lateral views.
Raw data must be available in DICOM format.
Disqualifiers
Cerebrovascular diseases not diagnosed or risk-assessed using DSA.
Patients with DSA image quality insufficient for image analysis and processing.
Severe organ diseases with an expected survival period of less than 2 years.
Inability to cooperate with treatment and follow-up.
Trial population
Patients with cerebrovascular disease can be evaluated for quantitative hemodynamic characteristics using QDSA.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
QDSA (Quantitative Digital Subtraction Angiography)
DeviceQDSA is a quantitative analysis technology based on DSA, used to assess hemodynamic characteristics and provide critical data support for the diagnosis and treatment of cerebrovascular diseases.
Treatment groups
1,000 Participants
are divided into 1 treatment groupGroup A: Testing populations1 intervention
Trial outcomes
Primary outcomes
1
Symptomatic stroke or death
Stroke is defined as a clinically symptomatic event (any new focal neurological deficit, seizure, or new-onset headache) that is associated with imaging findings of hemorrhage or infarction. Hemorrhage is defined as fresh intracranial blood on head computed tomography (CT) or magnetic resonance imaging (MRI), or in the cerebrospinal fluid. Infarction is defined as a new ischemic lesion on cranial CT or MRI (diffusion-weighted, T2-weighted, or fluid-attenuated inversion recovery MRI).
Time frame
After treatment (max 10 years)Secondary outcomes
1
Neurological status (modified Ranking Scale score)
The scale runs from 0-6, running from perfect health without symptoms to death. 0 - No symptoms. 1. No significant disability. Able to carry out all usual activities, despite some symptoms. 2. Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. 3. Moderate disability. Requires some help, but able to walk unassisted. 4. Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. 5. Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6. Dead
Time frame
After treatment (max 10 years)Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov